Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ) following its IPO. Seaport's Glyph prodrug platform has generated 24 drug candidates, with GlyphAllo for major depressive disorder (MDD) having entered Phase 2b clinical trials, with top-line data expected in the first half of 2027. Furthermore, Bristol Myers Squibb previously acquired Karuna Therapeutics, co-founded by Seaport CEO Daphne Zohar, for $14 billion, and Sharon Mates, former CEO of Intra-Cellular (which Johnson & Johnson once acquired), has joined Seaport's board of directors. These factors strengthen Seaport's ties with large pharmaceutical companies.